This prospective, single arm study aims to evaluate the preoperative neoadjuvant safety of
Sintilimab combined with XELOX plus bevacizumab in colorectal patients with liver metastasis
and pMMR/MSS status.
This preliminary prospective study aims to evaluate the safety of neoadjuvant treatment
combination of Sintilimab, XELOX and bevacizumab and also asses safety during surgery of
colorectal patients with liver metastasis and pMMR/MSS status.
To evaluate Pathological Remission Rate (pCR/MPR/PR rate), Objective Response Rate (ORR),
Recurrence Free Survival (RFS) and Overall Survival (OS).
Analysis of liver metastasis before and after treatment to compare molecular and
Patients receive Sintilimab + XELOX regimen every 3 weeks for 4 cycles and Bevacizumab every
3 weeks for 2 cycles. After which if there are no new lesions upon assessment, radical
surgery is performed within 6 weeks after neoadjuvant treatment. After surgery 4 cycles of
XELOX regimen is advised for adjuvant therapy.
Colorectal Cancer Metastatic, Metastatic Colorectal Cancer
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.